The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2017 | Ruxolitinib plus decitabine in post-MPN AML
The outcomes of patients with post-myeloproliferative neoplasm acute myeloid leukemia (post-MPN AML) are poor, with no standard therapy. In this interview, Farhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of the Phase I/II study (NCT02257138) of ruxolitinib plus decitabine in patients with post-MPN AML. He emphasizes that the interim results have demonstrated promising response rates in this subpopulation of patients, but will need further investigation to assess its safety and efficacy. This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
